870 related articles for article (PubMed ID: 28525961)
1. Passive and active immunization against respiratory syncytial virus for the young and old.
Villafana T; Falloon J; Griffin MP; Zhu Q; Esser MT
Expert Rev Vaccines; 2017 Jul; 16(7):1-13. PubMed ID: 28525961
[TBL] [Abstract][Full Text] [Related]
2. Respiratory syncytial virus in infants: is maternal vaccination a realistic strategy?
Munoz FM
Curr Opin Infect Dis; 2015 Jun; 28(3):221-4. PubMed ID: 25918956
[TBL] [Abstract][Full Text] [Related]
3. Prevention of Respiratory Syncytial Virus Infection: From Vaccine to Antibody.
Huang K; Wu H
Microbiol Spectr; 2014 Aug; 2(4):AID-0014-2014. PubMed ID: 26104207
[TBL] [Abstract][Full Text] [Related]
4. An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunization.
Raghunandan R; Lu H; Zhou B; Xabier MG; Massare MJ; Flyer DC; Fries LF; Smith GE; Glenn GM
Vaccine; 2014 Nov; 32(48):6485-92. PubMed ID: 25269094
[TBL] [Abstract][Full Text] [Related]
5. Protection of neonates and infants by maternal immunization.
Gerdts V; van Drunen Littel-van den Hurk S; Potter A
Expert Rev Vaccines; 2016 Nov; 15(11):1347-1349. PubMed ID: 27248694
[No Abstract] [Full Text] [Related]
6. A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants.
Zhu Q; McLellan JS; Kallewaard NL; Ulbrandt ND; Palaszynski S; Zhang J; Moldt B; Khan A; Svabek C; McAuliffe JM; Wrapp D; Patel NK; Cook KE; Richter BWM; Ryan PC; Yuan AQ; Suzich JA
Sci Transl Med; 2017 May; 9(388):. PubMed ID: 28469033
[TBL] [Abstract][Full Text] [Related]
7. Coadministration of Anti-Viral Monoclonal Antibodies With Routine Pediatric Vaccines and Implications for Nirsevimab Use: A White Paper.
Esposito S; Abu-Raya B; Bonanni P; Cahn-Sellem F; Flanagan KL; Martinon Torres F; Mejias A; Nadel S; Safadi MAP; Simon A
Front Immunol; 2021; 12():708939. PubMed ID: 34456918
[TBL] [Abstract][Full Text] [Related]
8. A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age.
August A; Glenn GM; Kpamegan E; Hickman SP; Jani D; Lu H; Thomas DN; Wen J; Piedra PA; Fries LF
Vaccine; 2017 Jun; 35(30):3749-3759. PubMed ID: 28579233
[TBL] [Abstract][Full Text] [Related]
9. Preventive and therapeutic strategies for respiratory syncytial virus infection.
Vujovic O; Mills J
Curr Opin Pharmacol; 2001 Oct; 1(5):497-503. PubMed ID: 11764776
[TBL] [Abstract][Full Text] [Related]
10. Preventing respiratory syncytial virus (RSV) disease in children.
Karron RA
Science; 2021 May; 372(6543):686-687. PubMed ID: 33986169
[No Abstract] [Full Text] [Related]
11. Safety and Immunogenicity of a Respiratory Syncytial Virus Fusion (F) Protein Nanoparticle Vaccine in Healthy Third-Trimester Pregnant Women and Their Infants.
Muňoz FM; Swamy GK; Hickman SP; Agrawal S; Piedra PA; Glenn GM; Patel N; August AM; Cho I; Fries L
J Infect Dis; 2019 Oct; 220(11):1802-1815. PubMed ID: 31402384
[TBL] [Abstract][Full Text] [Related]
12. Prevention of serious respiratory syncytial virus-related illness. II: Immunoprophylaxis.
Groothuis JR; Hoopes JM; Hemming VG
Adv Ther; 2011 Feb; 28(2):110-25. PubMed ID: 21318605
[TBL] [Abstract][Full Text] [Related]
13. Immunopathology of RSV infection: prospects for developing vaccines without this complication.
van Drunen Littel-van den Hurk S; Mapletoft JW; Arsic N; Kovacs-Nolan J
Rev Med Virol; 2007; 17(1):5-34. PubMed ID: 17004293
[TBL] [Abstract][Full Text] [Related]
14. Inferior immunogenicity and efficacy of respiratory syncytial virus fusion protein-based subunit vaccine candidates in aged versus young mice.
Cayatte C; Snell Bennett A; Rajani GM; Hostetler L; Maynard SK; Lazzaro M; McTamney P; Ren K; O'Day T; McCarthy MP; Schneider-Ohrum K
PLoS One; 2017; 12(11):e0188708. PubMed ID: 29182682
[TBL] [Abstract][Full Text] [Related]
15. Current strategies and perspectives for active and passive immunization against Respiratory Syncytial Virus in childhood.
Scotta MC; Stein RT
J Pediatr (Rio J); 2023; 99 Suppl 1(Suppl 1):S4-S11. PubMed ID: 36402228
[TBL] [Abstract][Full Text] [Related]
16. New strategies for control of respiratory syncytial virus infection.
Nokes JD; Cane PA
Curr Opin Infect Dis; 2008 Dec; 21(6):639-43. PubMed ID: 18978532
[TBL] [Abstract][Full Text] [Related]
17. Estimating the impact of multiple immunization products on medically-attended respiratory syncytial virus (RSV) infections in infants.
Rainisch G; Adhikari B; Meltzer MI; Langley G
Vaccine; 2020 Jan; 38(2):251-257. PubMed ID: 31740097
[TBL] [Abstract][Full Text] [Related]
18. Human respiratory syncytial virus: pathogenesis, immune responses, and current vaccine approaches.
Taleb SA; Al Thani AA; Al Ansari K; Yassine HM
Eur J Clin Microbiol Infect Dis; 2018 Oct; 37(10):1817-1827. PubMed ID: 29876771
[TBL] [Abstract][Full Text] [Related]
19. Vaccine Induced Herd Immunity for Control of Respiratory Syncytial Virus Disease in a Low-Income Country Setting.
Kinyanjui TM; House TA; Kiti MC; Cane PA; Nokes DJ; Medley GF
PLoS One; 2015; 10(9):e0138018. PubMed ID: 26390032
[TBL] [Abstract][Full Text] [Related]
20. Respiratory Syncytial Virus Maternal Vaccination in Infants below 6 Months of Age: Meta-Analysis of Safety, Immunogenicity, and Efficacy.
Mapindra MP; Mahindra MP; McNamara P; Semple MG; Clark H; Madsen J
Neonatology; 2024; 121(3):271-282. PubMed ID: 38286126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
